Video
Author(s):
Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.
Encorafenib/Binimetinib Induction Before Nivolumab/Ipilimumab Does Not Boost PFS in BRAF V600E/K+ Metastatic Melanoma
Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
AI Support Tool Demonstrates Detection Utility for Melanoma at Primary Care Practices
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Fox Chase Researcher Mitchell Fane Awarded $255,000 Grant to Explore Relationship Between Aging and Melanoma
Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC
Inavolisib Plus Palbociclib/Fulvestrant Bolsters PFS in HR+/HER2–, PIK3CA-Mutant Breast Cancer
Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC
Dr Freedland on Treatment Suspension and HRQoL During the EMBARK Trial in nmHSPC
Anthracycline Plus Chemo Associated With Improved RFS in MP High-2–Risk, HR+/HER2– Early Breast Cancer